C4 Therapeutics, Inc.
NASDAQ:CCCC
3.87 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | C4 Therapeutics, Inc. |
Symbool | CCCC |
Munteenheid | USD |
Prijs | 3.87 |
Beurswaarde | 273,179,430 |
Dividendpercentage | 0% |
52-weken bereik | 3.61 - 11.88 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Andrew J. Hirsch M.B.A. |
Website | https://www.c4therapeutics.com |
An error occurred while fetching data.
Over C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)